T-cell immunotherapy of cancer

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Adoptive transfer of T cells, combined with interleukin-2 (IL2), has shown success in eradicating tumors in animal models.
• Tumor-specific T cells are likely key therapeutic components within lymphokine-activated killer (LAK) or tumor-infiltrating lymphocyte (TIL) cell populations for human cancers such as melanoma and renal cell carcinoma.

Purpose of the Study:

• To investigate the therapeutic potential of cloned tumor-specific T cells in human cancers.
• To explore strategies for overcoming poor immunogenicity in common human tumors through vaccination.

Main Methods:

• Clinical trials with cloned tumor-specific T cells.
• Vaccination strategies involving IL2 or interferon-gamma (IFN gamma)-producing tumor cells.
• Targeted vaccination with peptides from mutated oncogenes (e.g., ras, p53) or breakpoint peptides (e.g., bcr/abl).

Main Results:

• While animal studies demonstrate tumor eradication via T cell transfer, human trials are necessary to confirm efficacy.
• Certain human tumors, like those associated with viruses (HPV, EBV), are potentially immunogenic.
• Most human tumors arising from point mutations are poorly immunogenic, necessitating novel therapeutic approaches.

Conclusions:

• Cloned tumor-specific T cells hold significant therapeutic promise for specific human cancers.
• Vaccination strategies targeting mutated oncogene products or viral antigens are viable approaches to enhance anti-tumor immunity.
• Further research and clinical trials are crucial to validate these immunotherapeutic strategies for a broader range of human cancers.